AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 141 min read$IPSC

Century Therapeutics (NASDAQ: IPSC) officer intends $4,994 sale of stock

Century Therapeutics officer Gregory Russotti plans to sell 2,587 shares, valued at $4,994, under Rule 144. The shares are from vested restricted stock and the sale includes funds to cover tax obligations. Previously, he sold 534 shares for $1,094.

Original reporting
stocktitan.net
Published Sep 14, 2026, 7:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IPSC
Neutral
high confidence
Mentioned
$IPSC
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$IPSCNeutralLow
01

Why it matters

The filing provides transparency but the modest size limits market impact.

02

Market read

Minor insider transaction with negligible trading relevance.

03

What to watch

The sale is to cover tax obligations, not a lack of confidence.

Relevance 4/10Novelty 3/10Timing: today

Background

Form 144 filings disclose planned sales of restricted securities.

Company-level read

Ticker impact

$IPSCNeutralHigh confidence
Context

Officer Gregory Russotti filed a Form 144 to sell 2,587 shares valued at $4,994.

Expected impact

Minimal downward pressure, likely negligible price move.

Evidence & confidence

The transaction size is tiny relative to market cap and unlikely to affect liquidity.

Market effects

Sector

No broader sector impact; biotech insider sales are routine.

Regional

Limited to U.S. investors tracking IPSC.

Global

None.

Counterpoint

What could challenge this read

Some traders may view any insider sale as a negative signal.

Key entities

  • Officer
    Gregory Russotti

    Officer of Century Therapeutics filing the sale.

  • Company
    Century Therapeutics

    Biotech firm listed on NASDAQ under IPSC.

Read at source← All news

Related articles

OCT 2
$IPSCMedAI 8/10

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics, Inc. (IPSC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026 Data demonstrated scalable production, in vivo function and immune evasion, and updated progress toward clinical dosing of CNTY-813, Centur

SEC EDGAR 8-K2 min
OCT 2
$IPSCMedAI 8/10

Century Therapeutics presents diabetes therapy data at EASD

Century Therapeutics (NASDAQ:IPSC) presented data on CNTY-813, a diabetes therapy, at the EASD meeting. The therapy showed long-term glycemic control in mouse models and successful engraftment in rats. The company plans to submit an IND application in Q4 2026, with clinical data expected in H2 2027, according to the press release.

investing.com2 min
OCT 2
$IPSCMed

Century Therapeutics' CNTY-813 Demonstrates Continued Advancement Toward the Clinic Via Nonclinical Data Presented at EASD 2026

Century Therapeutics (NASDAQ: IPSC) presented nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at EASD 2026. Data showed glycemic control in diabetic mice, scalable production, and immune evasion. The company expects to submit an IND application in Q4 2026 and anticipates initial clinical data in 2H 2027.

globenewswire.com3 min
AUG 18
$IPSCHighAI 8/10

Century Targets FDA Filing for Diabetes Cell Therapy

Century Therapeutics (NASDAQ: IPSC) aims to file for FDA approval of its diabetes cell therapy, CNTY-813, in Q4 2026, with initial human data expected in 2027. The company reported $197.2M in cash as of Q2 2026, sufficient to fund operations into Q1 2029. Preclinical results showed promising glucose control and immune evasion, but clinical outcomes are not guaranteed. Century also advances CNTY-308, a CAR-iT cell therapy, with IND-enabling work on track for 2026. Q2 R&D expenses decreased 27% to

mychesco.com3 min